AAN 2023: A unique opportunity to connect with the Global Neurology Community

Vanco Vlastimil (��ֳ� S.A.) — Fri, 21 Apr 2023 11:45:47 +0000

Donatello Crocetta, ��ֳ� Rare Disease Organization

Vanco Vlastimi… Fri 21/04/2023 - 13:45

Medical meetings and congresses like the American Academy of Neurology Annual Meeting provide a unique forum for the latest advances in research, medicine, and clinical practice to be, shared, presented, and discussed.

The massively varied progamme of scientific sessions, posters and symposia are an important way for delegates to stay up-to-date on the latest developments in the field. Because of the cross-functional and cross-cultural composition of attendees from around the world, there are often lively discussions and debates which can lead to new and unique perspectives being shared. These viewpoints can stimulate new approaches, important advances and, potentially, exciting improvements in patient care and treatment outcomes. They can also be a genesis for new collaborations and partnerships alongside opportunities for enriching professional development.

This spirit of collaboration, and a willingness to embrace perspectives outside our own experience, is crucial for advancing research and improving patient care. At ��ֳ�, we believe strongly that the best way to make a difference is to be part of the discussion. By working together as one community, our voice can be immeasurably amplified. Indeed, I believe by embracing this partnership approach we can make significant strides in better understanding complex neurological conditions, identifying new approaches to delivering improved patient outcomes.

Because we are focused on delivering differentiated patient value across multiple neurological therapy areas, the AAN meeting is a natural environment for ��ֳ� to connect with and learn from delegates from around world. We are united in our passion to better understand disease mechanisms which underpin the complex neurological diseases faced by patients. These insights help us to identify and develop new drug targets and therapies, and design clinical trials which resonate with the real-world outcomes patients value with the aim of improving patients' quality of life.

With our proud heritage in neurology, we’re excited to be sharing a diverse scientific programme at this year’s AAN congress, as we continue to pioneer new research into debilitating neurological conditions such as epilepsy and Parkinson’s disease, with the goal of improving patient outcomes and experiences. We’re also focusing our efforts toward communities living with rare diseases such as myasthenia gravis, autoimmune encephalitis and rare forms of epilepsy such as Dravet syndrome and Lennox-Gastaut syndrome. While individual rare diseases are uncommon, collectively they affect a significant portion of the population.

By taking a multi-faceted approach that focuses on increasing awareness and education, supporting patient advocacy, promoting research and innovation, improving access to care, and facilitating collaboration, we can work towards improving care for patients with rare diseases. Which is why, I’m so excited about the opportunity to connect with the community at this year’s AAN meeting!

Of course, there is still much work to be done. However, progress being made in rare disease research is inspiring, and continues to progress at pace. With continued research and open collaboration there is reason to believe both rare and more common diseases can be better understood and more effectively treated in the future.

about ucb

484 Likes

Bringing value to patients living with Parkinson’s disease

eCMSadmin — Thu, 22 Apr 2021 00:00:00 +0000

Bringing value to patients living with Parkinson’s disease

Martin Citron, Neurology Early Solutions

eCMSadmin Thu 22/04/2021 - 02:00

As the world’s neurology community gathers for the 73rd American Academy of Neurology (AAN) Annual Meeting, ��ֳ� is showcasing some of its early research in Parkinson’s disease. At ��ֳ�, developing new solutions for neurodegenerative diseases such as Parkinson’s disease is an important component of our early research programs - our long-term ambition is to change the treatment paradigm from symptom management to disease modification.

In the past drug development in Parkinson’s disease has mostly focused on the management of motor symptoms (e.g. tremor, rigidity, slowness of movement, balance problems). This has been quite positive within the early stages of the disease, where many symptoms can be controlled. We, and others in the industry, are now trying to get to the next level, improving not only symptoms, but slowing or halting the progression of disease based on our improved understanding of the pathological processes that drive disease progression.

Many neurodegenerative diseases are characterized by the aggregation of specific proteins, such as α-synuclein in Parkinson’s disease. By preventing α-synuclein from ‘clumping’, clearing it out, or stopping its spread from cell to cell, researchers believe they may prevent or slow Parkinson’s progression. This is a focus of our research at ��ֳ�. In addition, we are also looking at how we can help improve symptom management, particularly for people living with advanced Parkinson’s disease. Behind these development programs we are pursuing earlier stage research projects to address specific forms of Parkinson’s disease with gene therapy.

We are committed to helping develop new solutions for people living with Parkinson’s disease. Slowing of disease progression in Parkinson’s disease has not been demonstrated yet with any approach, but we are undaunted by the challenge.

about ucb

American Academy of Neurology AAN

700 Likes

AAN

AAN 2023: A unique opportunity to connect with the Global Neurology Community

Leave a Comment

Bringing value to patients living with Parkinson’s disease

Leave a Comment